Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Azadeh Nasrazadani"'
Publikováno v:
Cancers, Vol 16, Iss 6, p 1139 (2024)
Worldwide, breast cancer is the most frequently diagnosed malignancy in women, with triple-negative breast cancer (TNBC) being the most aggressive molecular subtype. Due to the dearth of effective therapeutic options for TNBC, novel agents targeting
Externí odkaz:
https://doaj.org/article/f9af5bb01c6145c7b4870ce4834da411
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 5, Iss , Pp 100147- (2022)
Oral hyperpigmentation is an infrequent phenomenon reported in the literature as a side effect that may be seen with the administration of certain chemotherapy agents such as doxorubicin. Given the under reported nature of mucosal hyperpigmentation,
Externí odkaz:
https://doaj.org/article/df23f35a470b46579730bdc0cb0c324c
Autor:
Neil Carleton, BS, Azadeh Nasrazadani, MD, Kristine Gade, MD, Sushil Beriwal, MD, Parul N Barry, MD, Adam M Brufsky, ProfMD, Rohit Bhargava, ProfMD, Wendie A Berg, ProfMD, Margarita L Zuley, ProfMD, G J van Londen, MD, Oscar C Marroquin, MD, Darcy L Thull, MS, Phuong L Mai, MD, Emilia J Diego, MD, Michael T Lotze, ProfMD, Steffi Oesterreich, ProfPhD, Priscilla F McAuliffe, MD, Adrian V Lee, ProfPhD
Publikováno v:
The Lancet. Healthy Longevity, Vol 3, Iss 1, Pp e54-e66 (2022)
Summary: Age is one of the most important risk factors for the development of breast cancer. Nearly a third of all breast cancer cases occur in older women (aged ≥70 years), with most cases being oestrogen receptor-positive (ER+). Such tumours are
Externí odkaz:
https://doaj.org/article/2bde87377c9a43b59d92fb5ad3ca37b4
Publikováno v:
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-6 (2020)
Abstract Amino-bisphosphonates such as zoledronic acid (ZA) can possibly ameliorate or prevent severe COVID-19 disease by at least three distinct mechanisms: (1) as immunostimulants which could boost γδ T cell expansion, important in the acute resp
Externí odkaz:
https://doaj.org/article/9a9c6b67d5e741d5b5acea9411af0b78
Publikováno v:
EBioMedicine, Vol 70, Iss , Pp 103489- (2021)
Externí odkaz:
https://doaj.org/article/b393eb6d1994466e9f6ebcfd2e096945
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
Aromatase inhibitors (AIs) are a key component in the chemoprevention and treatment of hormone receptor-positive (HR+) breast cancer. While the addition of AI therapy has improved cancer-related outcomes in the management of HR+ breast cancer, AIs ar
Externí odkaz:
https://doaj.org/article/91f8fd0165334196a90a3727462e844c
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
In recent decades, breast cancer has become largely manageable due to successes with hormone receptor targeting. Hormone receptor-positive tumors have favorable outcomes in comparison to estrogen receptor (ESR1, ER)/progesterone receptor-negative tum
Externí odkaz:
https://doaj.org/article/bcd6d05bdab646e6ad0e14b3e39a673b
Autor:
Peila Chen, Jamye F O'Neal, Nancy D Ebelt, Michael A Cantrell, Shreya Mitra, Azadeh Nasrazadani, Tracy L Vandenbroek, Lynn E Heasley, Carla L Van Den Berg
Publikováno v:
PLoS ONE, Vol 5, Iss 5, p e10443 (2010)
Oncogenes induce cell proliferation leading to replicative stress, DNA damage and genomic instability. A wide variety of cellular stresses activate c-Jun N-terminal kinase (JNK) proteins, but few studies have directly addressed the roles of JNK isofo
Externí odkaz:
https://doaj.org/article/2da32a800fd040dfb976b13b418185dc
Autor:
Osama Shiraz Shah, Azadeh Nasrazadani, Jennifer M. Atkinson, Celina Kleer, Priscilla F. McAuliffe, Rohit Bhargava, Jorge Reis-Filho, Peter C. Lucas, ADRIAN V. LEE, Steffi Oesterreich
Publikováno v:
Cancer Research. 83:PD4-07
Background Mixed invasive ductal and lobular carcinoma (mDLC) is a rare special subtype (3-6%, ~10,000 cases/annually in US) of invasive breast cancer with elusive pathophysiology. This entity exhibits a mix of ductal-like and lobular-like tumor sub-
Autor:
Jamie O. Brett, Taronish D. Dubash, Gabriela N. Johnson, Andrzej Niemierko, Veronica Mariotti, Leslie S.L. Kim, Jing Xi, Apurva Pandey, Siobhan Dunne, Azadeh Nasrazadani, Maxwell R. Lloyd, Avinash Kambadakone, Laura M. Spring, Douglas S. Micalizzi, Maristela L. Onozato, Dante Che, Utthara Nayar, Adam Brufsky, Kevin Kalinsky, Cynthia X. Ma, Joyce O'Shaughnessy, Hyo S. Han, Anthony J. Iafrate, Lianne Y. Ryan, Dejan Juric, Beverly Moy, Leif W. Ellisen, Shyamala Maheswaran, Nikhil Wagle, Daniel A. Haber, Aditya Bardia, Seth A. Wander
Publikováno v:
JCO Precision Oncology.
PURPOSE For patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) metastatic breast cancer (MBC), first-line treatment is endocrine therapy (ET) plus cyclin-dependent kinase 4/6 inhibition (CDK